Monika Pazgan−Simon

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu et al. · The Lancet · 2023 · 590 citations

First-line Therapy, Hepatology, International Phase 3 +8

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine

Piotr Rzymski, Monika Pazgan−Simon, Krzysztof Simon et al. · Vaccines · 2021 · 41 citations · Full text

Immunodeficiencies, Covid-19 Epidemiology, Vaccine Hesitancy +22

Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis.

Jolanta Zuwała−Jagiełło, Monika Pazgan−Simon, Krzysztof Simon et al. · Acta Biochimica Polonica · 2011 · 38 citations · Full text

Liver Fibrosis, Immunology, Liver Cirrhosis +21

Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

Monika Pazgan−Simon, Krzysztof Simon, Ewa Jarowicz et al. · Clinical and Experimental Hepatology · 2018 · 34 citations · Full text

Immunology, Hepatitis B, Pathology +21

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

Arndt Vogel, Stephen L. Chan, Zhenggang Ren et al. · Journal of Clinical Oncology · 2024 · 31 citations

Immunology, Pathology, Immunotherapeutics +24